Computed tomography-based radiomic model for the prediction of neoadjuvant immunochemotherapy response in patients with advanced gastric cancer

Table 1 Comparison of clinical characteristics between responders and non-responders, n (%)

Characteristics	Responders (n = 15)	Non-responders (n = 45)	P value
Age (years), average (mean ± SD)	57.53 (12.710)	58.64 (11.682)	0.756
Sex			0.856
Male	12 (80.0)	35 (77.8)
Female	3 (20.0)	10 (22.2)
Treatment cycles			0.579
2	2 (13.3)	8 (17.8)
3	9 (60.0)	20 (44.4)
4 +	4 (26.7)	17 (37.8)
Differentiation			0.526
High	1 (6.7)	1 (2.2)
Moderate	5 (33.3)	11 (24.4)
Poor	9 (60.0)	33 (73.3)
Primary tumor location			0.977
Cardia	3 (20.0)	8 (17.8)
Body	6 (40.0)	16 (35.6)
Antrum	4 (26.7)	14 (31.1)
Horn	2 (13.3)	7 (15.6)
PD-L1(22C3) CPS			0.237
≥ 5	10 (66.7)	26 (57.8)
< 5	5 (33.3)	19 (42.2)
CEA, median (IQR)	2.84 (0.93-17.84)	4.15 (1.75-9.52)	0.706
CA199, median (IQR)	9.08 (3.85-28.89)	16.23 (8.37-37.61)	0.264
T stage			0.004
1	4 (26.7)	0 (0)
2	1 (6.7)	4 (8.9)
3	3 (20.0)	18 (40.0)
4	7 (46.7)	23 (51.1)
N stage			0.044
0	0 (0)	1 (2.2)
1	11 (73.3)	18 (40.0)
2	4 (26.7)	18 (40.0)
3	0 (0)	8 (17.8)

The P value indicates a statistically significant difference between the responder and non-responder groups (P < 0.05). Responders: Patients with tumor regression grade 0-1 grade; Non-responders: Patients with tumor regression grade 2-3 grade; IQR: Interquartile range; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 19-9; PD-L1: Programmed death-ligand 1; CPS: Combined positive score.